Lifecore Biomedical Overview
Lifecore Biomedical (LNDC) has a ROE of 106.28%, above the Materials sector average of 19.42%.
Get informed when a big investor buys or sells
+ Follow106.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Lifecore Biomedical's return on equity stands at 106.28%. That is above the Materials sector average of 19.42%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Lifecore Biomedical sits higher the Materials benchmark (19.42%) with a ROE of 106.28%. That is roughly 447.2% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 106.28% for Lifecore Biomedical means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Lifecore Biomedical's ROE evolved across reporting periods, while the comparison chart places LNDC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Materials, ROE is commonly used to spot outliers. Lifecore Biomedical's reading of 106.28% (sector avg 19.42%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
